Group 1 - The core point of the news is that Baolingbao's stock price has experienced fluctuations, with a current price of 10.60 CNY per share, reflecting a year-to-date increase of 44.81% [1] - As of November 17, Baolingbao's market capitalization stands at 4.034 billion CNY, with a trading volume of 76.62 million CNY and a turnover rate of 1.93% [1] - The company has seen a net outflow of 5.7993 million CNY in principal funds, with significant buying and selling activity from large orders [1] Group 2 - Baolingbao Biotech Co., Ltd. is located in Dezhou, Shandong Province, and was established on October 16, 1997, with its listing date on August 28, 2009 [2] - The company's main business involves the research, production, and sales of functional sugars, with revenue composition including starch sugars (29.89%), sugar substitutes (26.55%), feed and by-products (22.40%), probiotics (13.48%), dietary fibers (7.39%), and others (0.29%) [2] - For the period from January to September 2025, Baolingbao achieved a revenue of 2.126 billion CNY, representing a year-on-year growth of 15.98%, and a net profit attributable to shareholders of 134 million CNY, up 32.58% [2]

Group 1 - The stock of Baolingbao fell by 5.02% on October 21, closing at 9.28 CNY per share, with a trading volume of 77.45 million CNY and a turnover rate of 2.23%, resulting in a total market capitalization of 3.532 billion CNY [1] - Baolingbao Biotech Co., Ltd. is located in Dezhou, Shandong Province, and was established on October 16, 1997, with its listing date on August 28, 2009. The company's main business involves the research, production, and sales of functional sugars [1] - The revenue composition of Baolingbao includes: starch sugars and others 29.89%, sugar-reduced sweeteners 26.55%, feed and by-products 22.40%, probiotics 13.48%, dietary fiber 7.39%, and others (supplements) 0.29% [1] Group 2 - From the perspective of the top ten holdings of funds, one fund under Western Li De has a significant position in Baolingbao. The Western Li De New Fortune Mixed A Fund (673120) held 14,400 shares in the second quarter, accounting for 4.17% of the fund's net value, ranking as the seventh largest holding [2] - The Western Li De New Fortune Mixed A Fund (673120) was established on June 16, 2017, with a latest scale of 1.8184 million. Year-to-date, it has lost 5.36%, ranking 8106 out of 8162 in its category; over the past year, it has lost 7.13%, ranking 7959 out of 8024; since inception, it has achieved a return of 27.84% [2] Group 3 - The fund manager of Western Li De New Fortune Mixed A (673120) is Zhang Changping, who has been in the position for 4 years and 352 days. The total asset scale of the fund is 1.568 billion CNY, with the best fund return during his tenure being 111.93% and the worst being 0.88% [3]

Company Overview - Baolingbao Bio-Technology Co., Ltd. is located in Dezhou, Shandong Province, and was established on October 16, 1997. The company was listed on August 28, 2009. Its main business involves the research, production, and sales of functional sugars [1][2]. Financial Performance - For the first half of 2025, Baolingbao achieved operating revenue of 1.399 billion yuan, representing a year-on-year growth of 18.02%. The net profit attributable to shareholders was 92.672 million yuan, reflecting a year-on-year increase of 33.66% [2]. - Since its A-share listing, Baolingbao has distributed a total of 309 million yuan in dividends, with 95.072 million yuan distributed over the past three years [3]. Stock Performance - As of September 24, Baolingbao's stock price increased by 2.20% to 9.77 yuan per share, with a total market capitalization of 3.714 billion yuan. The stock has seen a year-to-date increase of 33.47%, but has declined by 4.96% over the past five trading days, 16.85% over the past 20 days, and 23.73% over the past 60 days [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent occurrence on May 22, where it recorded a net buy of -50.8373 million yuan [1]. Shareholder Information - As of September 10, Baolingbao had 34,400 shareholders, a decrease of 6.59% from the previous period. The average number of circulating shares per shareholder increased by 7.06% to 10,739 shares [2]. Business Segments - The main revenue composition of Baolingbao includes: starch sugars and others (29.89%), sugar-reducing sweeteners (26.55%), feed and by-products (22.40%), probiotics (13.48%), dietary fiber (7.39%), and others (0.29%) [1]. Industry Classification - Baolingbao belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically under the subcategory of agricultural product processing, and is involved in various concept sectors including sugar substitutes, synthetic biology, biomedicine, small-cap stocks, and participation in the New Third Board [2].